Connected profiles1
Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Recurrent Castration-Sensitive Prostate Carcinoma peptide trials
1 selected ClinicalTrials.gov records carrying the official condition label Recurrent Castration-Sensitive Prostate Carcinoma. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
1 selected records.
Connected peptides
1 profiles.
Registry update years
2026–2026 in selected records.
Indication intelligence
Selected evidence landscape
Trial phases1
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 2 (1)
Registry statuses1
Overall statuses at each retained observation, not necessarily current today.
Recruiting (1)
Across the connected peptide profiles, PeptideScanner also carries 46 selected PubMed records and 24 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Recurrent Castration-Sensitive Prostate Carcinoma unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT06378866
PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- July 20, 2026
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Leuprolide · 2026-07-20
ClinicalTrials.gov record NCT06378866
Recruiting at the retained observation.
Open attributed record →